stars 1 stars 2 stars 3

DermaXon targets the brain-skin connection to discover and develop novel therapeutic strategies to treat life-threatening diseases and disorders such as pain, pruritus and genetic disorders of skin keratinization. The company core technology is based on the design and development of small molecules modulating multiple targets or inhibiting the degradation of endogenous molecules exhibiting polypharmacology. This polypharmacological approaches aim to understand and optimize the unknown off-targets activities for existing small molecules such as cannabinoids or retinoic acid. DermaXon uses medicinal chemistry, molecular biology and RNA sequencing to characterize and identify synergies and overlaps between biological signaling pathways modulated by small molecules.

DermaXon Questions

The DermaXon annual revenue was $8 million in 2026.

1 people are employed at DermaXon.

DermaXon is based in Missoula, Montana.

The NAICS codes for DermaXon are [54, 541, 541714, 5417, 54171].

The SIC codes for DermaXon are [873, 87].

Top DermaXon Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users